Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Expression Tech, Eden Biodesign Form Co-marketing Pact

NEW YORK (GenomeWeb News) — Oxford Expression Technologies and Eden Biodesign have struck a co-marketing agreement to serve pharmaceutical researchers involved in protein expression.

Under the agreement, OET will offer access to Eden Biodesign's process development, clinical trial current good manufacturing practice services. Eden Biodesign's customers, in turn, will be able to use OET's range of baculovirus capabilities for their individual protein expression requirements. In particular, Eden's customers will have access to OET's experience in troubleshooting baculovirus expression and the use of its flashback technology for increasing protein yield in difficult to express proteins.

OET was founded in 2007 by a collaboration between Oxford Brookes University and the Natural Environment Research Council to provide custom proteins for research purposes.

Eden Biodesign is focused on guiding clients through process development, manufacturing, regulatory and technology transfer challenges.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more